API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Prochlorperazine maleate inhibits the action of a chemical called dopamine in the brain by blocking D2 dopamine receptors in the brain. It can also block histaminergic, cholinergic, and noradrenergic receptors. It is indicated for the treatment of schizophrenia.
Lead Product(s): Prochlorperazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Compazine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg is approximately $30.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
Lead Product(s): Prochlorperazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Prochlorperazine Maleate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biophore India Pharmaceuticals Pvt Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022